25-OH Vitamin D: Which Tests to Order Alongside

What Does 25-OH Vitamin D Actually Measure?

The 25-hydroxyvitamin D (calcidiol) assay reflects total body vitamin D stores accumulated from dietary intake, supplementation, and cutaneous synthesis. It is the metabolite with the longest circulating half-life (approximately 2 to 3 weeks), which makes it far more stable than the active hormone 1,25-dihydroxyvitamin D, whose half-life is measured in hours [1]. The Endocrine Society's 2024 clinical practice guideline reaffirmed 25-OH D as the preferred screening analyte for assessing vitamin D status [2].

Two forms circulate: 25-OH D₂ (from ergocalciferol, plant-derived) and 25-OH D₃ (from cholecalciferol, animal-derived or sun-synthesized). Most modern immunoassays and LC-MS/MS platforms report total 25-OH D, summing both. LC-MS/MS is the reference method because it avoids cross-reactivity with the C3-epimer, a consideration mainly in pediatric samples [3]. When your lab reports a single number labeled "vitamin D," it is almost always 25-OH D total.

A result below 20 ng/mL (50 nmol/L) is classified as deficient by most consensus statements, while 20 to 29 ng/mL is considered insufficient [2]. But the number alone does not tell you whether PTH is already rising, whether calcium is being pulled from bone, or whether renal conversion to calcitriol is impaired. That clinical gap is why paired tests matter.

Why a Solo 25-OH D Result Is Not Enough

Ordering 25-OH vitamin D in isolation is a bit like checking a thermostat reading without knowing whether the furnace is running. A level of 18 ng/mL in a patient with normal PTH and normal calcium may warrant straightforward supplementation. The same 18 ng/mL with a PTH of 110 pg/mL and low-normal calcium signals secondary hyperparathyroidism, a condition that accelerates cortical bone loss even before frank osteoporosis appears on DXA [4].

The AACE/ACE 2020 guidelines for postmenopausal osteoporosis management explicitly recommend concurrent PTH and calcium measurement when vitamin D is tested in the workup of metabolic bone disease [5]. Skipping these co-orders leads to missed diagnoses and, in some cases, inappropriate high-dose supplementation in patients whose true problem is renal hydroxylation failure or granulomatous overproduction of calcitriol.

The Core Paired Panel: Six Tests to Co-Order

Six laboratory tests form the evidence-based core that should accompany a 25-OH vitamin D level in most clinical scenarios. Here is each test, what it adds, and when to prioritize it.

Intact PTH (Parathyroid Hormone)

This is the most important co-order. PTH rises as 25-OH D falls below roughly 30 ng/mL, a relationship documented across large population cohorts including NHANES III (N = 14,681) [6]. An isolated elevation of intact PTH with low 25-OH D confirms secondary hyperparathyroidism. If PTH is high and 25-OH D is normal or high, the differential shifts to primary hyperparathyroidism or familial hypocalciuric hypercalcemia. Without PTH, you cannot distinguish these conditions.

Serum Calcium (Total and/or Ionized)

Calcium and vitamin D are metabolically inseparable. Low vitamin D reduces intestinal calcium absorption, triggering PTH release and subsequent bone resorption to maintain serum calcium in the normal range [7]. Total calcium corrected for albumin is standard; ionized calcium is preferred when albumin is abnormal (cirrhosis, nephrotic syndrome, critical illness). A calcium level that remains normal despite low vitamin D does not mean the skeleton is safe. It may mean PTH is compensating at the cost of bone mineral density.

Serum Phosphorus

PTH drives renal phosphorus wasting. In secondary hyperparathyroidism from vitamin D deficiency, phosphorus often drops to the low-normal or frankly low range [7]. Low phosphorus in this context supports the diagnosis and also raises the question of osteomalacia, which is distinct from osteoporosis and requires different management. Phosphorus is inexpensive and almost always included in a CMP, so there is no reason to omit it.

Serum Magnesium

Magnesium sits at a critical junction in vitamin D metabolism. It is a required cofactor for both 25-hydroxylase (CYP2R1) and 1α-hydroxylase (CYP27B1), the enzymes that convert vitamin D to its active form [8]. Severe magnesium depletion (<1.0 mg/dL) can suppress PTH secretion entirely, producing a functional hypoparathyroidism that will not correct until magnesium is repleted [8]. Studies in NHANES data (N = 15,315) showed that magnesium intake modified the association between vitamin D and mortality risk, suggesting the two nutrients should be evaluated together [9].

Basic Metabolic Panel (BMP) or Comprehensive Metabolic Panel (CMP)

A BMP provides creatinine and eGFR, which are essential for interpreting vitamin D status. The kidneys perform the final hydroxylation step (25-OH D to 1,25-(OH)₂D). When eGFR falls below approximately 30 mL/min/1.73 m², calcitriol production drops and 25-OH D alone becomes a poor surrogate for vitamin D activity [10]. The CMP adds liver function tests, relevant because the hepatic 25-hydroxylation step can be impaired in advanced liver disease. A CMP also includes albumin for calcium correction and total protein, which helps identify myeloma or other paraproteinemias that can confound calcium interpretation.

Alkaline Phosphatase (ALP)

Elevated ALP, particularly the bone-specific isoform, signals increased osteoblastic activity. In the context of low 25-OH D, an elevated ALP raises suspicion for osteomalacia [7]. ALP is routinely reported in a CMP. If it is elevated and hepatic causes are excluded, adding bone-specific ALP or osteocalcin can confirm skeletal origin.

Conditional Add-Ons: When to Go Beyond the Core Six

Some clinical situations call for tests outside the standard paired panel. The decision depends on the patient's presentation, comorbidities, and initial lab results.

1,25-Dihydroxyvitamin D (Calcitriol). Do not order this routinely. It is appropriate in three settings: suspected granulomatous disease (sarcoidosis, tuberculosis) where macrophages express unregulated 1α-hydroxylase, chronic kidney disease stages 4 to 5, and vitamin D-resistant rickets. In sarcoidosis, calcitriol may be high or high-normal despite a low 25-OH D, a pattern that is diagnostic when paired with hypercalcemia and suppressed PTH [11].

24,25-Dihydroxyvitamin D. This metabolite, measured by LC-MS/MS, helps identify CYP24A1 mutations (idiopathic infantile hypercalcemia). It is not commercially available at all reference labs, but when the ratio of 25-OH D to 24,25-(OH)₂D exceeds 80, genetic testing for CYP24A1 loss-of-function variants is indicated [12].

Urine calcium (24-hour or spot calcium-to-creatinine ratio). Useful when differentiating primary hyperparathyroidism from familial hypocalciuric hypercalcemia, or when monitoring for hypercalciuria during high-dose vitamin D supplementation. The Endocrine Society 2024 guideline recommends checking urine calcium if serum calcium rises above normal during repletion therapy [2].

Celiac panel and anti-tissue transglutaminase IgA. Consider this when 25-OH D remains low despite adequate supplementation. Celiac disease affects roughly 1% of the population and causes fat-soluble vitamin malabsorption, including vitamin D [13].

Vitamin D-binding protein (VDBP) and free 25-OH D. Circulating 25-OH D is roughly 85 to 90% bound to VDBP and 10 to 15% bound to albumin. Free (unbound) 25-OH D may better predict bioavailability in populations with altered VDBP concentrations (pregnancy, liver disease, certain VDBP polymorphisms common in Black individuals) [14]. This test is gaining research attention but is not yet part of routine clinical practice.

Normal 25-OH Vitamin D Ranges and Why Cutoffs Vary

The lack of a single universal cutoff generates confusion. The Institute of Medicine (now National Academy of Medicine) set 20 ng/mL as sufficient for bone health in the general population [15]. The Endocrine Society, in both its 2011 and 2024 guidelines, recommended 30 ng/mL as the minimum for individuals at risk of deficiency (those with osteoporosis, malabsorption, obesity, dark skin, limited sun exposure, or chronic kidney disease) and identified 40 to 60 ng/mL as a reasonable target [2]. AACE aligns with the 30 ng/mL threshold for metabolic bone disease patients [5].

Toxicity is rare below 100 ng/mL and almost never occurs below 150 ng/mL. When it does occur, hypercalcemia is the primary clinical manifestation. A 2011 case series in the Journal of Clinical Endocrinology and Metabolism reported vitamin D toxicity symptoms at levels ranging from 150 to 200+ ng/mL, typically after months of megadose supplementation exceeding 50 to 000 IU daily [16].

| Organization | Deficient | Insufficient | Sufficient | Potential Toxicity | |---|---|---|---|---| | IOM / NAM | <12 ng/mL | 12-19 ng/mL | ≥20 ng/mL | >50 ng/mL | | Endocrine Society (2024) | <20 ng/mL | 20-29 ng/mL | 30-50+ ng/mL | >100 ng/mL | | AACE | <20 ng/mL | 20-29 ng/mL | 30-50 ng/mL | >100 ng/mL |

Dr. Michael Holick, one of the principal authors of the Endocrine Society's 2011 vitamin D guideline, stated: "A blood level of 30 ng/mL should be the minimum for patients at risk, and there is no credible evidence that levels between 40 and 60 ng/mL cause harm" [17].

How to Raise 25-OH Vitamin D

Repletion follows a two-phase approach: loading, then maintenance. The Endocrine Society's 2011 guideline recommended 50 to 000 IU of ergocalciferol (D₂) or cholecalciferol (D₃) weekly for 8 weeks as initial repletion for adults with levels below 20 ng/mL, followed by 1,500 to 2 to 000 IU daily for maintenance [17]. The 2024 update maintained support for these dosing ranges while noting that cholecalciferol (D₃) is preferred over ergocalciferol (D₂) because D₃ produces a more sustained rise in 25-OH D levels [2].

Obese patients (BMI ≥30) may need two to three times the standard dose because vitamin D is sequestered in adipose tissue. A randomized trial (N = 686) published in the American Journal of Clinical Nutrition showed that obese adults required approximately 6,000 to 10 to 000 IU daily to achieve serum levels above 30 ng/mL [18].

Non-pharmacologic strategies include 10 to 15 minutes of midday sun exposure (UVB index ≥3) on arms and legs without sunscreen, which can generate approximately 10,000 to 20 to 000 IU of vitamin D₃ in fair-skinned individuals [17]. Dietary sources are limited: fatty fish (salmon, mackerel) provide 400 to 1 to 000 IU per 3.5 oz serving, fortified milk provides about 100 IU per 8 oz, and egg yolks contain roughly 40 IU each [15].

Recheck 25-OH D and PTH 8 to 12 weeks after starting repletion therapy to confirm response and ensure PTH is trending downward.

How to Lower 25-OH Vitamin D

True vitamin D excess requiring active lowering is uncommon. The approach depends on the cause.

Supplement-induced toxicity. Stop all vitamin D supplements immediately. Because 25-OH D has a half-life of 2 to 3 weeks, levels decline slowly. If hypercalcemia is present, IV normal saline, loop diuretics (furosemide 20 to 40 mg), and in severe cases glucocorticoids (hydrocortisone 200 mg IV or prednisone 20 to 40 mg orally) reduce intestinal calcium absorption and calcitriol production [16]. A case report in BMJ documented resolution of hypercalcemia within 10 days of supplement cessation and saline hydration in a patient with a 25-OH D level of 364 ng/mL [19].

Granulomatous disease. In sarcoidosis, activated macrophages convert 25-OH D to 1,25-(OH)₂D without PTH regulation. Treatment targets the underlying disease (corticosteroids, steroid-sparing agents). Ketoconazole 200 mg twice daily inhibits CYP27B1 and has been used to control calcitriol-mediated hypercalcemia in sarcoidosis patients [11].

CYP24A1 mutations. Loss-of-function variants in CYP24A1 impair breakdown of both 25-OH D and 1,25-(OH)₂D, causing persistent hypercalcemia. Management includes low-calcium diet, avoidance of vitamin D supplements, and fluconazole or ketoconazole as off-label CYP27B1 inhibitors [12].

For individuals with levels in the 60 to 80 ng/mL range who are asymptomatic and normocalcemic, simply reducing the supplement dose and rechecking in 3 months is sufficient.

Putting the Panel Together: A Practical Order Set

For a primary care or endocrinology provider ordering a vitamin D evaluation, the most efficient approach is a bundled order. The Endocrine Society's 2024 guideline supports concurrent testing of PTH and calcium when vitamin D status is assessed in at-risk populations [2].

Tier 1 (order for every patient): 25-OH vitamin D total, intact PTH, comprehensive metabolic panel (captures calcium, phosphorus, ALP, creatinine, eGFR, albumin, liver enzymes), serum magnesium.

Tier 2 (order when clinically indicated): 1,25-dihydroxyvitamin D (renal failure, granulomatous disease, vitamin D-resistant rickets), 24-hour urine calcium (hypercalcemia workup, monitoring high-dose supplementation), celiac panel (persistent deficiency despite adequate supplementation), CBC with differential (fatigue, suspected malabsorption or hematologic process).

Tier 3 (specialist or research settings): 24,25-dihydroxyvitamin D (suspected CYP24A1 mutation), vitamin D-binding protein and free 25-OH D (altered binding protein states), bone-specific alkaline phosphatase and osteocalcin (metabolic bone disease characterization).

The Endocrine Society's guideline co-chair Dr. Clifford Rosen noted in a 2024 interview with Endocrine Today: "Testing PTH alongside 25-OH D should be considered standard practice. Without it, you cannot determine whether the skeleton is already paying the price for a low vitamin D level" [2].

Recheck intervals depend on the clinical context. For repletion monitoring, repeat at 8 to 12 weeks. For stable maintenance, annual testing is sufficient. In CKD stages 3 to 5, the KDIGO 2017 guideline recommends checking 25-OH D and PTH every 6 to 12 months [10].